Aktiesnakken — Juni 2010
-
så må genmab jo genåbne aftalen og betale med fremtidig profit, færre royalties
-
og så må GSK overtage alle udgifter fremadrettet med Arzerra
-
eller også må GSK tegne overkurs i en emission.
-
der er ikke så mange flere muligheder i den konstruktion
-
tjaaa, det har de jo ikke noget ud af at blande sig i. Sådan er det jo med andre firmaer
-
Nordicom A/S - Opnåelse af betingede tilsagn for minimum DKK 50 mio
-
-
GES monthly update stadig ikke kommet.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind